The Nipro Group promotes research and development of both medical equipment and pharmaceutical products.

Our research and development focuses on cutting-edge technologies as well as trying to achieve higher quality and improved functionality with our existing products. We expect to commercialize one of our cutting-edge products, namely our nerve regeneration-assisting device, which uses our unique bio-absorbable materials, developed in-house.

We have come close to developing a cell-culturing system thanks to our studies of stem cells in umbilical blood.

In terms of artificial organs, our range of implanted ventricular-assist devices, developed in cooperation with an American company, are currently at the clinical testing stage in Japan.

With regard to the development of new drugs and new formulation technologies, further to the commercialization of our powdered dialysis solutions based on a new and highly effective granulation technology, we plan to be the first company to commercialize a double-bag product for hemodiafiltration substitution fluids as well as selling various products such as pre-filled syringes for safety use, thereby contributing to the prevention of medical accidents.

In this consolidated accounting year, the total cost of R&D activity was 4.8 billion yen (US$ 52.1 million).